EGFR amplifications were detected in 50% of the TCGA-GBM and 89% of the Intellance-2 samples.29 This difference fits with the patient selection criterion from these cohorts since EGFR amplification was an inclusion criterium for the Intellance-2 phase II trial. Here, EGFR is linked to glioblastoma.